molecule comparisons, page-3

No problem Supertramp.

There were a few reasons for my post...

1. To compare the mechanisms of action of each of the molecules in the clinic (or about to go in the clinic). This was such an important point I wanted to emphasize. Did you read that article I highlighted? Very interesting.

2. In the AGM Address the CEO highlighted that full results for Neuren's Fragile X project were presented at a national neuropsychiatry meeting in April and were being prepared for submission as a peer-reviewed paper. That's certainly submitted now. Only 4-5 months before it's published. It will (a) raise the profile of the Fragile X program; (b) the company will get the information about what they're doing out to investigators, funding sources and potential partners; (c) it's a high priority for the company to move on this.

3. That Pharma are certainly aware of the latest Neuren Fragile X results and I would not be surprised if they are in discussions, even if, it's very early in the game.

Regards,
Tony